Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET
Company Participants
Jenene Thomas - Investor Relations
Walter Klemp - Chairman and Chief Executive Officer
John Paul Waymack - Senior Chief Medical Officer
Jonathan Foster - Executive Vice President and Chief Financial Officer
Conference Call Participants
Jonathan Aschoff - ROTH MKM
Jeff Jones - Oppenheimer
Operator
Hello and welcome to the Moleculin Biotech Q1 2023 Quarterly Update Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
It is now my pleasure to turn the call over to your host Jenene Thomas, Investor Relations. Please go ahead, Jenene.
Jenene Thomas
Thank you, Kevin. Good morning, and welcome, everyone.
At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the Safe Harbor provisions of the federal securities laws and are based on Moleculin's current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements.
Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's Web site, and on the Securities and Exchange Commission's Web site. We encourage you to review these documents carefully.
Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own estimates and research. While the company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified and makes no representation as to the adequacy, fairness, accuracy or completeness of or that any independent source has verified any information obtained from the third-party sources. Any data discussed regarding clinical trials in progress are considered preliminary and subject to change.
Joining us on today's call from Moleculin's leadership team are Walter Klemp, Chairman and Chief Executive Officer; Dr. John Paul Waymack, Senior Chief Medical Officer; and Jonathan Foster, Executive Vice President and Chief Financial Officer.
I would now like to turn the call over to Wally Klemp, Chairman and CEO. Wally, please proceed.